Abstract 478P
Background
Lung cancer is commonly diagnosed after 40 years old and surgical lung resection is the recommended treatment for early stage lung cancer. The mean age of presentation is around 70 years old but there remained concerns on performing surgery in these patients. These concerns were addressed with advances in surgical technique and we aimed to review our experience of performing curative lung resection in patients above 70 years old.
Methods
We performed a retrospective review of all patients who underwent curative surgery for primary lung cancers between 2018 and 2021 and compared the outcome between patients 70 years old and above against those who were younger.
Results
289 were reviewed, of which 180 patients (62.3%) were under 70 years old and 109 patients (37.7%) were 70 years old and above. Patients above 70 years had a significantly higher incidence of hypertension, hyperlipidemia, diabetes mellitus, ischaemic heart disease and renal impairment but there was no significant difference in the incidence of previous stroke, atrial fibrillation, congestive heart failure and chronic obstructive pulmonary disease. There was also no significant difference between the pre-operative FEV1 and DLCO between the 2 groups of patients. Patients above 70 years old were at higher risk of developing pneumonia (OR 2.28, 95% CI 1.65-3.13, p = 0.003), respiratory failure (OR 2.71, 95% CI 2.33-3.16, p = 0.020) and unplanned return to the ICU (OR 2.41, 95% CI 1.78-3.27, p = 0.005). Peri-operative mortality was also higher in patients above 70 years old but this was statistically not significant. (OR 1.94, CI 1.18-3.17, p = 0.073). There was no significant difference in the post-operative incidence of cardiac, renal or wound complications. No patients developed a peri-operative stroke.
Conclusions
Our study demonstrated that patients above 70 years old may be more susceptible to pulmonary complications such as pneumonia and respiratory failure that may in turn lead to higher peri-operative mortality. Care can be taken to mitigate these complications such as pre-operative pulmonary rehabilitation and early mobilisation but this should not preclude patients above 70 years old from undergoing curative lung resection surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract